Mandeep S. Sagoo

About Mandeep S. Sagoo

My work has been motivated by how rapidly ocular oncology is changing – and how we make sure patients truly benefit from that change. Survival remains fundamental, but my focus has been on preserving the eye, vision, and long-term quality of life, while ensuring innovation is translated safely into everyday clinical practice.

A major driver has been improving care pathways for ocular tumours. By strengthening shared-care models, we’ve helped reduce delays in referral and investigation, clarified escalation thresholds, and enabled more patients to be safely monitored closer to home. This has improved consistency of care while preserving specialist access and oversight. In parallel, I’ve worked with colleagues to advocate for patients in underserved settings, through my work in global ophthalmology and the Rb-Net retinoblastoma program.

My interest in biotechnology for ocular oncology has strongly shaped my work. Advances in precision oncology, drug delivery systems, antibody-drug conjugates, and biologics offer enormous potential, but they also introduce new challenges. My focus has been on anticipating these by developing practical frameworks for monitoring and treatment, as well as leading clinical trials, so that emerging therapies can be adopted safely and sustainably.

I’ve also continued to explore how machine-learning approaches can support clinical decision-making in uveal naevi and melanoma, particularly in predicting which tumours need to be treated, local recurrence and treatment response. The aim is to move toward more personalized surveillance and therapeutic strategies — reducing unnecessary visits for low-risk patients while detecting high-risk change earlier.

Finally, survivorship has become an increasingly important part of my work. Through digitally engineered 3D-printed ocular prosthetics, we’re demonstrating how technology, imaging, and additive manufacturing can improve cosmetic accuracy, reduce production time, and enhance patient-reported outcomes following enucleation.

Overall, my aim has been to help move ocular oncology toward a more holistic, biotechnology-enabled model of care – one that balances innovation with safety, improves outcomes that matter to patients, and raises standards across ophthalmology.